GALGT2 (B4GALNT2 ) is an experimental gene therapy for Duchenne muscular dystrophy (DMD) being developed by Sarepta Therapeutics and tested in collaboration with the Nationwide Children’s Hospital in the U.S.
How it works
GALGT2 gene therapy uses adenovirus-based vectors (AAVs) to deliver the GALGT2 gene to the body. Adenoviral vectors are commonly used for gene therapy. They are not harmful because any disease-causing genes have been removed. The rAAVrh74-vector is designed in a way that makes the GALGT2 gene active in skeletal and heart muscle cells — the kind of cells that are affected in DMD.
The GALGT2 gene provides instructions to build a protein that upregulates, or increases, the production of other proteins essential for muscle function. Because it does not replace the defective gene itself (the DMD gene), the therapy is called surrogate gene therapy. Surrogate therapy has not only the potential to correct muscle pathologies, or abnormalities, that are caused by mutations in the DMD gene, but also other muscular dystrophies, such as limb girdle muscular dystrophy 2A (LGMD2A) and congenital muscular dystrophy type 1a (MDC1A).
GALGT2 in clinical trials
A preclinical study in a mouse model of DMD assessed the effect of GALGT2 gene therapy on heart function. The mice carried a mutation in the DMD gene that leads to an almost complete absence of the dystrophin protein. One group of mice received GALGT2 gene therapy one day after birth. At three months of age, the therapy had significantly improved heart function and cardiac output — the amount of blood pumped from the heart — compared with control mice. A second group of mice was treated at two months of age and was analyzed 15 months later. GALGT2-treated mice again had better heart function than control mice. GALGT2 gene therapy was well-tolerated, suggesting that the treatment is not toxic at the tested doses.
An open-label Phase 1/2 clinical trial (NCT03333590) assessing the safety and efficacy of GALGT2 gene therapy is ongoing. Six patients with DMD receive either a low dose or a high dose of GALGT2 gene therapy, which is injected into both legs. They are evaluated regularly for up to 24 months after treatment. Efficacy is evaluated by a functional six-minute walk test, and by direct muscle testing for strength. The study is no longer recruiting and results are expected in November of 2021.
People who have been infected with adenovirus in the past may have developed antibodies against AAV, which may interfere with the success of treatment. For this reason, patients undergoing gene therapy need to be screened for AAV antibodies.
Last updated: Oct. 28, 2019
Muscular Dystrophy News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.